News

As Preventive, H2RA Poses Risks for Patients on Clopidogrel After Bleeding Ulcer

Author and Disclosure Information

Key clinical point: Compared with PPIs, H2RAs pose more risks – on both GI and cardiovascular fronts – as a preventive in patients with atherosclerosis and a history of peptic ulcer bleeding.

Major finding: After 48 weeks, 1.7% of patients in the pantoprazole (PPI) group (n = 60) suffered significant upper GI events; 13.3% of patients in the famotidine (H2RA) group (n = 60) did (P = 0.017). Cardiovascular events were also more common in the H2RA group.

Data source: Randomized prospective study of 120 patients with history of peptic ulcer bleeding (but not at initial endoscopy) assigned to pantoprazole (40 mg daily) or famotidine (40 mg daily) for 48 weeks.

Disclosures: The study is hospital funded. The authors report no disclosures.


 

AT DDW® 2016

References

SAN DIEGO – New research suggests histamine-2 receptor antagonists aren’t a viable alternative to proton pump inhibitors to prevent recurrence of bleeding peptic ulcers in clopidogrel users.

U.S. and European agencies have warned of interactions between proton pump inhibitors (PPIs) and clopidogrel. But a study presented at the annual Digestive Disease Week finds significant upper GI events were much more common in patients who took famotidine (Protonix), a histamine-2 receptor antagonist (H2RA), compared with those who took pantoprazole (Pepcid), a PPI, as a preventive treatment.

Dr. Ping-I Hsu

“The findings will change the practice of some physicians who prescribe H2RA to prevent UGI [upper GI] events in clopidogrel users,” said study lead author Dr. Ping-I Hsu, chief of gastroenterology at Kaohsiung Veterans General Hospital and professor of medicine at National Yang-Ming University, both in Taiwan.

Currently, Dr. Hsu said, “physicians often use PPIs to prevent ulcer complications in clopidogrel users because it is the only drug proven useful in the prevention of peptic ulcers and ulcer complications in clopidogrel users.”

But “both the U.S. Food & Drug Administration and the European Medicines Agency have posted safety warnings and discourage the use of PPIs with clopidogrel unless absolutely necessary,” he said.

Enter the prospect of H2RA medications as an alternative. The new study, Dr. Hsu said, is the first to explore the GI protection effect and safety of H2RAs in patients on clopidogrel monotherapy.

The randomized prospective study followed 120 patients with a history of peptic ulcer bleeding (but not at initial endoscopy) and atherosclerosis. All long-term users of ADP receptor antagonists, they were assigned to pantoprazole (40 mg daily) or famotidine (40 mg daily) for 48 weeks.

Patients were examined via endoscopy when they experienced events like severe epigastric discomfort.

The famotidine group had more significant upper GI events (13.3%) than the pantoprazole group (1.7%). Diarrhea was equal in both groups (1.7%). Pneumonia was comparable (0% and 1.7% for pantoprazole and famotidine, respectively), as was fracture (1.7% and 0%).

Wider differences were found in acute myocardial infarction (1.5% and 4.5%), and cerebral vascular accident (0% and 3.4%) for pantoprazole and famotidine, respectively.

According to Dr. Hsu, three earlier studies linked concurrent use of PPIs and clopidogrel to significant increases in cardiovascular events. But this study linked a higher cardiac risk to the H2RA medication.

The researchers found no differences between the drugs in sequential changes of serum magnesium levels and bone mineral densities.

Dr. Hsu made this recommendation to physicians: “Please don’t use H2RAs to prevent peptic ulcer or ulcer complications in clopidogrel users. It is ineffective to prevent UGI [upper GI] events in clopidogrel users who have a history of ulcer bleeding. PPIs can effectively prevent UGI events in clopidogrel users with a history of ulcer bleeding.”

In addition, he said, the risk of thrombotic events is lower on a PPI.

Recommended Reading

Exercise Linked to Fewer Cardiovascular Events in Nonmetastatic Breast Cancer Patients
Clinician Reviews
Lipoprotein(a) and Cardiovascular Disease
Clinician Reviews
“Go Low” or “Say No” to Aggressive Systolic BP Goals?
Clinician Reviews
Persistent Cough, Peculiar Heart Sound
Clinician Reviews
Flu Vaccination Cut Hospitalizations in Heart Failure Patients
Clinician Reviews
The Cruise With No Snooze
Clinician Reviews
Sweet Spot Found for LDL-C Reduction to Minimize Risk
Clinician Reviews
Long-acting Opioids Increase Cardiovascular Deaths in Noncancer Patients
Clinician Reviews
Simplify Cardiac Risk Assessment for Rheumatologic Conditions
Clinician Reviews
Methylphenidate Tied to Greater Risk for Arrhythmia in Children, Adolescents
Clinician Reviews